CASE REPORT

Laparoscopic hepatopancreaticoduodenectomy for synchronous gallbladder cancer and extrahepatic cholangiocarcinoma: a case report

Guo-Liang Yao*

Abstract

Background: Hepatopancreaticoduodenectomy (HPD) is one of the most complex procedures, and it is very rarely reported. Laparoscopic HPD (LHPD) is even rarer. To date, there are only 3 reports of LHPD for locally advanced gallbladder cancer (GBC) or extrahepatic cholangiocarcinoma (ECC). This is the first report of LHPD for synchronous GBC and ECC.

Case presentation: A 75-year-old female patient complained of jaundice for 2 weeks without fever or abdominal pain. She was diagnosed with synchronous GBC and ECC. After a comprehensive preparation, she underwent a laparoscopic pancreaticoduodenectomy and resection of hepatic segments of IVb and V, and her digestive tract reconstruction followed Child's methods. She was discharged on the 12th day postoperatively without pancreatic leakage, biliary leakage, or liver failure.

Conclusions: LHPD is safe and feasible for selected cases of GBCs or ECCs.

Keywords: Hepatopancreaticoduodenectomy, Hepatopancreatoduodenectomy laparoscopy, Gallbladder cancer, Extrahepatic cholangiocarcinoma

Background

Hepatopancreaticoduodenectomy (HPD) is one of the most complicated operations which includes hepatectomy and pancreaticoduodenectomy. This operation was first reported in 1974 by Kasumi for locally advanced gallbladder cancer (GBC) [1]. Almost half a century passed, this procedure was not universally accepted. In total, no more than 1000 HPDs have been reported [2, 3] for the past 50 years because of the high morbidity and mortality [4–6]. After a comprehensive search of PubMed using the terms of laparoscopy, hepatopancreaticoduodenectomy, hepatopancreatoduodenectomy, hepatopancrectomy, pancreaticoduodenectomy, and hepatectomy, there were only 3 reports [7–9] involving 3 laparoscopic HPDs (LHPD) for locally advanced GBC or extrahepatic cholangiocarcinoma (ECC) which were listed in detail in Table 1. To our knowledge, this case is the first LHPD for concurrent GBC and ECC.

*Correspondence: ygl1982@sina.cn
Department of General Surgery, The First Affiliated Hospital of Henan University of Science and Technology, 24 Jinghua road, Luoyang 471000, China
**Table 1** Summary of the published cases

| Author     | Country   | Year | Diagnosis | Gender | Age (y) | Operation                        | Operation duration (min) | Intraoperation blood loss (ml) | Hospitalization (d) | Main complication             |
|------------|-----------|------|-----------|--------|---------|----------------------------------|--------------------------|------------------------------|---------------------|-----------------------------|
| Zhang MZ   | China     | 2014 | ECC       | Male   | 61      | LPD + LRH                        | 600                      | 450                          | 16                  | Biliary leakage              |
| Chong EH   | South Korea | 2019 | ECC       | Female | 73      | LPD + LLH<sup>a</sup>            | 510                      | 350                          | 16                  | Cystitis                    |
| James M    | India     | 2021 | GBC       | Male   | 73      | LPD + segments of IVb + V        | 610                      | 500                          | 12                  | Delayed gastric empty        |

LPD Laparoscopic Pancreaticoduodenectomy, LRH Laparoscopic Right Hemihepatectomy, GBC Gallbladder Cancer, LLH Laparoscopic Left Hemihepatectomy

<sup>a</sup> Laparoscopic resection and robotic reconstruction
Case report
A 75-year-old female patient complained of jaundice without fever or abdominal pain for 2 weeks and was diagnosed with ECC with GBC by enhanced CT and MRI. She denied any history of cardiovascular or pulmonary system problems. Her physical examination was negative except for jaundice of her skin and sclera. Her routine laboratory tests were as follows: hemoglobin 108 g/L, total bilirubin 222.8 μmol/L, direct bilirubin 158 μmol/L, plasma albumin 35.2 g/L, ALT 297 U/L, AST 192 U/L, ALP 403 U/L, and γGGT 394 U/L. Her tumor markers were normal, except for a mildly elevated Ca19-9 of 34.06 U/ml. Her hemostatic function was normal. An enhanced CT and MRI revealed that there was irregular thickening of the common bile duct wall and the gallbladder (Fig. 1). Cytological examination by ERCP was performed with the result of a malignant tumor of the lower common bile duct.

The patient was placed in a supine position with the legs split. Five ports were employed for the operation with an additional port located subxiphoid for splitting the liver. First, resection of the gallbladder was planned and then fast-frozen pathology was performed due to the presence of a malignant tumor. Pancreatocoduodenectomy was performed by artery-first approach. First, the superior mesenteric artery was retropancreatically dissected, the stomach and pancreatic neck were transected, and finally, the common hepatic duct was transected. The hepatectomy was performed along the intrahepatic Glissonian pedicle. The ligamentum teres hepati was dissected to reveal the pedicle of a segment of IVb. The pedicle was transected, and the liver was continuously split until reaching the right anterior branch of the portal vein. Split liver and transected middle hepatic vein to further reveal the pedicle of segment V and then transected it (Fig. 1).

Reconstruction was performed following Child’s methods. Pancreatocojunostomy was completed by the modified Blumgart method. Cholangiojunostomy was completed by 4–0 polydioxanone in a manner of a continuous suture. The gastroenterostomy was completed by an endolinear stapler.

The operation lasted 380 min with an estimated blood loss of 400 ml. Her postoperative treatment followed the principle of enhanced recovery after the operation (ERAS). Her recovery was smooth without pancreatic leakage, biliary leakage, or liver failure. She was discharged on the 12th day postoperatively. The pathology revealed synchronous adenosquamous carcinoma of the gallbladder and common bile duct. This pathological result was finally given after a comprehensive discussion. The diagnosis of adenosquamous carcinoma was based on immunohistochemistry which showed both squamous cell carcinoma and adenocarcinoma. The diagnosis of dual original carcinoma instead of GBC with seeding metastasis to a common biliary duct was based on the fact of extensive lesion of the lower biliary duct without a clear boundary.

Discussion
The indications for hepatopancreatoduodenectomy (HPD) are locally advanced gallbladder cancer (GBC) and locally advanced extrahepatic cholangiocarcinoma (ECC) [3]. HPD is one of the most challenging procedures, which includes pancreatocoduodenectomy (PD) and hepatectomy. This combination results in a dramatic increase in the morbidity and mortality, especially in the risk of liver failure [4–6], which prevents its use. As reported, the morbidity of HPD is as high as 80%, and the in-hospital mortality may be more than 10% [3]. This rate is far higher than that of other operations, such as hepatectomy and PD. However, this increased mortality may be a result of the major hepatectomy, as the results from HPD with minor hepatectomy showed no increases in the mortality [10]. The survival results were promising for the patients who had HPD. The 3-year and 5-year overall survival rates were reported to be 48% and 37% [11], respectively, which were significantly higher than those of unresectable tumors [12]. The prolonged survival has encouraged surgeons to try this procedure.

As laparoscopic techniques have progressed, more and more complicated operations are completed by laparoscopy [13, 14] with an acceptable complication. Post-operation pancreatic leakage is considered to be the biggest obstacle to PD. Recent years, several modifications [15, 16] of pancreaticojejunosotomy have been published to lessen the complication with success. Now, more and more laparoscopic pancreatocoduodenectomy (LPD) are reported with less pancreatic leakage and less blood loss [17]. The laparoscopic anatomic hepatectomy (LAH) also results in less blood loss and faster recovery [18]. In recent years, we have routinely carried out these complicated operations; therefore, we first adopted laparoscopy for HPD with success. LHDP has only been reported for 3 patients with locally advanced GBC or ECC, which were considered the main indications [19]. All the 3 operations were successful with acceptable complications which were listed in detail in Table 1. This was the first LHDP for concurrent GBC and ECC. Our experience showed that LHDP was safe and feasible. Our successful performance of the LHDP may be based on two factors. First, surgeon preparation should be emphasized. Surgeons who are interested in LHDP should be skilled in both LPD and LAH. Well-trained surgeons can perform LPD fluently.
with less morbidity [17]. LAH was also reported to lower morbidity following the intrahepatic Glissonean approach by skilled surgeons [18]. Only surgeons who were skilled at both of the complicated procedures can perform LHPD with safety. Second, the patient selection is important. As the increased morbidity may be secondary to the major hepatectomy, this combination of operations should be limited to a minor hepatectomy. Those patients who need a major hepatectomy should undergo a preoperative portal vein embolism (PVE). The results from patients who had a preoperative PVE showed less morbidity and less in-hospital mortality [20]. Preoperative bile drainage is controversial, as no significant advantage was shown according to published data [21]. Preoperative bile drainage should be recommended for those patients who need major hepatectomy or those with cholangitis [22], as jaundice may affect the remnant liver function [23]. Patients who plan to undergo LHPD should be at good performance status. The case reported here by our team was an elderly female patient who had no limitations in her daily life.

Conclusions
According to the published cases and our experience, LHPD is safe and feasible by specially skilled surgeons. LHPD should be an option for selected patients with GBC or ECC.

Abbreviations
HPD: Hepatopancreaticoduodenectomy; LHPD: Laparoscopic hepatopancreaticoduodenectomy; GBC: Gallbladder cancer; ECC: Extrahepatic cholangiocarcinoma; ERAS: Enhanced recovery after an operation; PD: Pancreaticoduodenectomy; LPD: Laparoscopic pancreaticoduodenectomy; LAH: Laparoscopic anatomic hepatectomy; PVE: Portal vein embolism.

Acknowledgements
Not applicable.

Authors' contributions
Yao GL performed this operation and wrote this manuscript. The authors read and approved the final manuscript.
Funding
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study was approved by the committee of The First Affiliated Hospital of Henan University of Science and Technology. The patient gave a written consent to participate in this trial.

Consent to publication
Not applicable.

Competing interests
The author declares no competing interests.

Received: 8 November 2021 Accepted: 9 May 2022
Published online: 09 June 2022

References
1. Kasumi F, Takagi K, Konishi T, Sakamoto G. Treatment of gallbladder cancer. Jpn J Gastroenterol Surg. 1976;9:170–7.
2. Fancellu A, Sanna V, Deiana G, Ninnini C, Turilli D, Perri T, et al. Current role of hepatopancreatoduodenectomy for the management of gallbladder cancer and extrahepatic cholangiocarcinoma: a systematic review. World J Gastrointest Oncol. 2021;13:625–37.
3. Zhou Y, Zhang Z, Wu L, Li B. A systematic review of safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers. HPB. 2016;18:1–6.
4. Dai WC, Chok KS, Cheung TT, Chan AC, Chan SC, Lo CM. Hepatopancreatoduodenectomy for advanced hepatobiliary malignancies: a single-center experience. Hepatobiliary Pancreat Dis Int. 2017;16:382–6.
5. Welch JC, Gleeson EM, Karachirostis A, Pitt HA. Hepatopancreatoduodenectomy in North America: are the outcomes acceptable? HPB. 2020;22:360–7.
6. D’Souza MA, Valdimarsson VT, Campagnaro T, Cauchy F, Chatzizacharias NA, D’Hondt M, et al. Hepatopancreatoduodenectomy - a controversial treatment for bile duct and gallbladder cancer from a European perspective. HPB. 2020;22:1389–48.
7. Zhang MZ, Xu XW, Mou YF, Yan JF, Zhu YP, Zhang PC, et al. Resection of a cholangiocarcinoma via laparoscopic hepatopancreatoduodenectomy: a case report. World J Gastrointest Endosc. 2014;20:17260–4.
8. Chong EH, Choi SH. Hybrid laparoscopic and robotic hepatopancreatoduodenectomy for cholangiocarcinoma. J Gastrointest Surg. 2019;23:1947–8.
9. James M, Kalayarasan R, Gnanasekaran S, Pottakkat B. Laparoscopic hepatopancreatoduodenectomy for locally advanced gall bladder cancer. J Min Access Surg. 2017;13:369–72.
10. Hemming AW, Magliocca JF, Fujita S, Kayler LK, Hochwald S, Zendejas I, et al. Combined resection of the liver and pancreas for malignancy. J Am Coll Surg. 2010;210:808–14.
11. Shimizu A, Motoyama H, Kubota K, Notake T, Fukushima K, Ikehara T, et al. Safety and oncological benefit of hepatopancreatoduodenectomy for advanced extrahepatic cholangiocarcinoma with horizontal tumor spread: Shinshu University Experience. Ann Surg Oncol. 2021;28:1202–25.
12. Fiteri F, Jary M, Monnier F, Nguyen T, Beohou E, Demarchi M, et al. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterol. 2014;14:143.
13. Morano WF, Shaikh MF, Gleeson EM, Galvez A, Khalli M, Lieb J, et al. Reconstruction options following pancreatoduodenectomy after Roux-en-Y gastric bypass: a systematic review. World J Surg Oncol. 2018;16:168.
14. Yamamoto M, Zaima M, Yamamoto H, Harada H, Kavamura J, Yamada M, et al. New laparoscopic procedure for left-sided pancreatic cancer-artery-first approach laparoscopic RAMPS using 3D technique. World J Surg Oncol. 2017;15:213.
15. Wu T, Guo Y, Bi J, Liu S, Guo Y, Bao S. Modified duct-to-mucosa versus conventional pancreaticoenterostomy for pancreatoduodenectomy: a retrospective cohort study based on propensity score matching analysis. World J Surg Oncol. 2019;17:5.
16. Wang D, Liu X, Wu H, Liu K, Zhou X, Liu J, et al. Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreatoduodenectomy. World J Surg Oncol. 2020;18:75.
17. Liu M, Ji S, Xu W, Liu W, Qin Y, Hu Q, et al. Laparoscopic pancreaticoduodenectomy: are the best times coming? World J Surg Oncol. 2019;17:81.
18. Ji WB, Wang HG, Zhao ZM, Duan WD, Lu F, Dong JH. Robotic-assisted laparoscopic anatomic hepatectomy in China: initial experience. Ann Surg. 2011;253:342–8.
19. Ebata T, Yokoyama Y, Igarashi T, Sugawara G, Mizuno T, Nogino M. Review of hepatopancreatoduodenectomy for biliary cancer: an extended radical approach of Japanese origin. J Hepatobiliary Pancreat Sci. 2014;21:550–5.
20. Ebata T, Yokoyama Y, Igarashi T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.
21. Fang Y, Gurusamy KS, Wang Q, Davidson BR, Lin H, Xie X, et al. Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg. 2013;100:1589–96.
22. Vauthney JH, Pawlik TM, Abdalla EK, Anees JF, Nemr RA, Wei SH, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg. 2004;239:722–30.
23. Iacono C, Ruzzenente A, Campagnaro T, Bortolasi V, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg. 2013;257:191–204.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions